Department of Ophthalmology, Roski Eye Institute, University of Southern California, Los Angeles, California, USA.
Curr Opin Neurol. 2020 Feb;33(1):93-105. doi: 10.1097/WCO.0000000000000777.
Optic neuropathies refer to a collection of diseases in which retinal ganglion cells (RGCs), the specialized neuron of the retina whose axons make up the optic nerve, are selectively damaged. Blindness secondary to optic neuropathies is irreversible as RGCs do not have the capacity for self-renewal and have a limited capacity for self-repair. Numerous strategies are being developed to either prevent further RGC degeneration or replace the cells that have degenerated. In this review, we aim to discuss known limitations to regeneration in central nervous system (CNS), followed by a discussion of previous, current, and future strategies for optic nerve neuroprotection as well as approaches for neuro-regeneration, with an emphasis on developments in the past two years.
Neuro-regeneration in the CNS is limited by both intrinsic and extrinsic factors. Environmental barriers to axon regeneration can be divided into two major categories: failure to clear myelin and formation of glial scar. Although inflammatory scars block axon growth past the site of injury, inflammation also provides important signals that activate reparative and regenerative pathways in RGCs. Neuroprotection with neurotrophins as monotherapy is not effective at preventing RGC degeneration likely secondary to rapid clearance of growth factors. Novel approaches involve exploiting different technologies to provide sustained delivery of neurotrophins. Other approaches include application of anti-apoptosis molecules and anti-axon retraction molecules. Although stem cells are becoming a viable option for generating RGCs for cell-replacement-based strategies, there are still many critical barriers to overcome before they can be used in clinical practice. Adjuvant treatments, such as application of electrical fields, scaffolds, and magnetic field stimulation, may be useful in helping transplanted RGCs extend axons in the proper orientation and assist with new synapse formation.
Different optic neuropathies will benefit from neuro-protective versus neuro-regenerative approaches. Developing clinically effective treatments for optic nerve disease will require a collaborative approach that not only employs neurotrophic factors but also incorporates signals that promote axonogenesis, direct axon growth towards intended targets, and promote appropriate synaptogenesis.
视神经病变是指一组疾病,其中视网膜神经节细胞(RGCs),即视网膜的特化神经元,其轴突构成视神经,选择性地受损。由于 RGCs 没有自我更新的能力,自我修复能力有限,因此视神经病变导致的失明是不可逆转的。目前正在开发许多策略来防止 RGC 进一步退化或替代已退化的细胞。在这篇综述中,我们旨在讨论中枢神经系统(CNS)再生的已知限制,然后讨论以前、当前和未来的视神经神经保护策略以及神经再生方法,重点介绍过去两年的发展。
中枢神经系统的神经再生受到内在和外在因素的限制。轴突再生的环境障碍可分为两大类:髓鞘清除失败和胶质瘢痕形成。虽然炎症性瘢痕阻止了轴突在损伤部位以外的生长,但炎症也提供了重要的信号,激活了 RGC 中的修复和再生途径。神经生长因子作为单一疗法的神经保护作用在预防 RGC 退化方面并不有效,可能是由于生长因子的快速清除。新方法涉及利用不同的技术提供神经营养因子的持续递送。其他方法包括应用抗细胞凋亡分子和抗轴突回缩分子。虽然干细胞正在成为基于细胞替代的策略产生 RGC 的可行选择,但在它们可用于临床实践之前,仍有许多关键障碍需要克服。辅助治疗,如应用电场、支架和磁场刺激,可能有助于移植的 RGC 以适当的方向延伸轴突并促进新的突触形成。
不同的视神经病变将受益于神经保护与神经再生方法。开发视神经疾病的临床有效治疗方法需要一种协作方法,不仅使用神经营养因子,还整合促进轴突发生、引导轴突向预期目标生长和促进适当突触形成的信号。